Drug intelligence / Profile preview

LP-00C

Development stage: Preclinical
Lead developer: Longbio Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

LP-00C is a preclinical-stage bi-functional antibody or fusion protein developed by Longbio Pharma for the treatment of B lymphocyte-mediated autoimmune diseases. While the specific molecular targets of LP-00C have not been publicly disclosed, the therapeutic candidate is engineered to modulate B-cell activity, which is central to the pathology of various autoimmune conditions. The drug is being developed using Longbio's proprietary protein engineering platforms aimed at creating next-generation biologics with enhanced efficacy and safety profiles compared to traditional monoclonal antibodies.

Beyond the preview

Go deeper on LP-00C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-00C.

Explore the full profile